Download PDF
CC BY 4.0 · Thromb Haemost 2019; 119(01): 104-116
DOI: 10.1055/s-0038-1676344
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Human Platelet Protein Ubiquitylation and Changes following GPVI Activation

Amanda J. Unsworth   *
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
2   Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom
,
Izabela Bombik   *
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
,
Adan Pinto-Fernandez
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
,
Joanna F. McGouran
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
,
Rebecca Konietzny
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
,
René P. Zahedi
4   JGH Proteomics Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
,
Steve P. Watson
5   Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
6   Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, The Midlands, United Kingdom
,
Benedikt M. Kessler   **
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
,
Catherine J. Pears   **
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
› Author Affiliations Funding This work was supported by grants from The British Heart Foundation (Grant references PG/11/121/29308 and PG/14/17/30720) and the EPA Cephalosporin Fund.
Further Information

Publication History

04 June 2018

10 October 2018

Publication Date:
31 December 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Platelet activators stimulate post-translational modification of signalling proteins to change their activity or their molecular interactions leading to signal propagation. One covalent modification is attachment of the small protein ubiquitin to lysine residues in target proteins. Modification by ubiquitin can either target proteins for degradation by the proteasome or act as a scaffold for other proteins. Pharmacological inhibition of deubiquitylases or the proteasome inhibition of platelet activation by collagen, demonstrating a role for ubiquitylation, but relatively few substrates for ubiquitin have been identified and the molecular basis of inhibition is not established. Here, we report the ubiquitome of human platelets and changes in ubiquitylated proteins following stimulation by collagen-related peptide (CRP-XL). Using platelets from six individuals over three independent experiments, we identified 1,634 ubiquitylated peptides derived from 691 proteins, revealing extensive ubiquitylation in resting platelets. Note that 925 of these peptides show an increase of more than twofold following stimulation with CRP-XL. Multiple sites of ubiquitylation were identified on several proteins including Syk, filamin and integrin heterodimer sub-units. This work reveals extensive protein ubiquitylation during activation of human platelets and opens the possibility of novel therapeutic interventions targeting the ubiquitin machinery.

Keywords

platelets - sites of ubiquitinylation - GPVI - deubiquitylation inhibition

* These authors contributed equally to this study.


** B.M.K. and C.J.P. are joint corresponding authors.


Supplementary Material

 

  • References

  • 1 Hughes CE, Pollitt AY, Mori J. , et al. CLEC-2 activates Syk through dimerization. Blood 2010; 115 (14) 2947-2955
    CrossrefPubMedSearch in Google Scholar
  • 2 Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3. EMBO J 1997; 16 (21) 6414-6425
    CrossrefPubMedSearch in Google Scholar
  • 3 Poole A, Gibbins JM, Turner M. , et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16 (09) 2333-2341
    CrossrefPubMedSearch in Google Scholar
  • 4 Grabbe C, Husnjak K, Dikic I. The spatial and temporal organization of ubiquitin networks. Nat Rev Mol Cell Biol 2011; 12 (05) 295-307
    CrossrefPubMedSearch in Google Scholar
  • 5 Yau R, Rape M. The increasing complexity of the ubiquitin code. Nat Cell Biol 2016; 18 (06) 579-586
    CrossrefPubMedSearch in Google Scholar
  • 6 Bremm A, Komander D. Emerging roles for Lys11-linked polyubiquitin in cellular regulation. Trends Biochem Sci 2011; 36 (07) 355-363
    PubMedSearch in Google Scholar
  • 7 Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem 2017; 86: 159-192
    CrossrefPubMedSearch in Google Scholar
  • 8 Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008; 121 (04) 567-571
    CrossrefPubMedSearch in Google Scholar
  • 9 Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 2004; 92 (01) 171-177
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Gupta N, Li W, Willard B, Silverstein RL, McIntyre TM. Proteasome proteolysis supports stimulated platelet function and thrombosis. Arterioscler Thromb Vasc Biol 2014; 34 (01) 160-168
    CrossrefPubMedSearch in Google Scholar
  • 11 Gupta N, Li W, McIntyre TM. Deubiquitinases modulate platelet proteome ubiquitination, aggregation, and thrombosis. Arterioscler Thromb Vasc Biol 2015; 35 (12) 2657-2666
    CrossrefPubMedSearch in Google Scholar
  • 12 Dangelmaier CA, Quinter PG, Jin J, Tsygankov AY, Kunapuli SP, Daniel JL. Rapid ubiquitination of Syk following GPVI activation in platelets. Blood 2005; 105 (10) 3918-3924
    CrossrefPubMedSearch in Google Scholar
  • 13 Auger JM, Best D, Snell DC, Wilde JI, Watson SP. c-Cbl negatively regulates platelet activation by glycoprotein VI. J Thromb Haemost 2003; 1 (11) 2419-2426
    CrossrefPubMedSearch in Google Scholar
  • 14 Yankee TM, Keshvara LM, Sawasdikosol S, Harrison ML, Geahlen RL. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain. J Immunol 1999; 163 (11) 5827-5835
    PubMedSearch in Google Scholar
  • 15 Thomas DH, Getz TM, Newman TN. , et al. A novel histidine tyrosine phosphatase, TULA-2, associates with Syk and negatively regulates GPVI signaling in platelets. Blood 2010; 116 (14) 2570-2578
    CrossrefPubMedSearch in Google Scholar
  • 16 Reppschläger K, Gosselin J, Dangelmaier CA. , et al. TULA-2 protein phosphatase suppresses activation of Syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346, a regulatory site of Syk. J Biol Chem 2016; 291 (43) 22427-22441
    CrossrefPubMedSearch in Google Scholar
  • 17 Zhou Y, Abraham S, Renna S. , et al. TULA-2 (T-Cell Ubiquitin Ligand-2) inhibits the platelet fc receptor for IgG IIA (FcγRIIA) signaling pathway and heparin-induced thrombocytopenia in mice. Arterioscler Thromb Vasc Biol 2016; 36 (12) 2315-2323
    CrossrefPubMedSearch in Google Scholar
  • 18 Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. Curr Opin Hematol 2009; 16 (05) 329-333
    CrossrefPubMedSearch in Google Scholar
  • 19 Watson SP, Bahou WF, Fitzgerald D, Ouwehand W, Rao AK, Leavitt AD. ; ISTH Platelet Physiology Subcommittee. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost 2005; 3 (09) 2098-2101
    CrossrefPubMedSearch in Google Scholar
  • 20 O'Neill EE, Brock CJ, von Kriegsheim AF. , et al. Towards complete analysis of the platelet proteome. Proteomics 2002; 2 (03) 288-305
    CrossrefPubMedSearch in Google Scholar
  • 21 Burkhart JM, Vaudel M, Gambaryan S. , et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120 (15) e73-e82
    CrossrefPubMedSearch in Google Scholar
  • 22 Fong KP, Barry C, Tran AN. , et al. Deciphering the human platelet sheddome. Blood 2011; 117 (01) e15-e26
    CrossrefPubMedSearch in Google Scholar
  • 23 Brophy TM, Raab M, Daxecker H. , et al. RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin alpha(IIb)beta3. Biochem Biophys Res Commun 2008; 369 (04) 1088-1093
    CrossrefPubMedSearch in Google Scholar
  • 24 Pears CJ, Thornber K, Auger JM. , et al. Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. PLoS One 2008; 3 (11) e3793
    CrossrefPubMedSearch in Google Scholar
  • 25 Nielsen ML, Vermeulen M, Bonaldi T, Cox J, Moroder L, Mann M. Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry. Nat Methods 2008; 5 (06) 459-460
    CrossrefPubMedSearch in Google Scholar
  • 26 Sobott F, Watt SJ, Smith J, Edelmann MJ, Kramer HB, Kessler BM. Comparison of CID versus ETD based MS/MS fragmentation for the analysis of protein ubiquitination. J Am Soc Mass Spectrom 2009; 20 (09) 1652-1659
    CrossrefPubMedSearch in Google Scholar
  • 27 Bustos D, Bakalarski CE, Yang Y, Peng J, Kirkpatrick DS. Characterizing ubiquitination sites by peptide-based immunoaffinity enrichment. Mol Cell Proteomics 2012; 11 (12) 1529-1540
    CrossrefPubMedSearch in Google Scholar
  • 28 Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138 (01) 141-143
    CrossrefPubMedSearch in Google Scholar
  • 29 Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 2003; 75 (03) 663-670
    CrossrefPubMedSearch in Google Scholar
  • 30 Davis S, Charles PD, He L, Mowlds P, Kessler BM, Fischer R. Expanding proteome coverage with CHarge Ordered Parallel Ion aNalysis (CHOPIN) combined with broad specificity proteolysis. J Proteome Res 2017; 16 (03) 1288-1299
    CrossrefPubMedSearch in Google Scholar
  • 31 Ternette N, Yang M, Laroyia M. , et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Reports 2013; 3 (03) 689-700
    CrossrefPubMedSearch in Google Scholar
  • 32 Tyanova S, Temu T, Sinitcyn P. , et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016; 13 (09) 731-740
    CrossrefPubMedSearch in Google Scholar
  • 33 Vizcaíno JA, Deutsch EW, Wang R. , et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 2014; 32 (03) 223-226
    CrossrefPubMedSearch in Google Scholar
  • 34 Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep 2009; 10 (11) 1250-1258
    PubMedSearch in Google Scholar
  • 35 Wagner SA, Beli P, Weinert BT. , et al. Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 2012; 11 (12) 1578-1585
    CrossrefPubMedSearch in Google Scholar
  • 36 Beck F, Geiger J, Gambaryan S. , et al. Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. Blood 2017; 129 (02) e1-e12
    CrossrefPubMedSearch in Google Scholar
  • 37 Arthur JF, Shen Y, Gardiner EE. , et al. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 2011; 9 (01) 163-172
    CrossrefPubMedSearch in Google Scholar
  • 38 Cappadocia L, Lima CD. Ubiquitin-like protein conjugation: structures, chemistry, and mechanism. Chem Rev 2018; 118 (03) 889-918
    CrossrefPubMedSearch in Google Scholar
  • 39 Hwaiz R, Rahman M, Zhang E, Thorlacius H. Platelet secretion of CXCL4 is Rac1-dependent and regulates neutrophil infiltration and tissue damage in septic lung damage. Br J Pharmacol 2015; 172 (22) 5347-5359
    CrossrefPubMedSearch in Google Scholar
  • 40 Goggs R, Williams CM, Mellor H, Poole AW. Platelet Rho GTPases-a focus on novel players, roles and relationships. Biochem J 2015; 466 (03) 431-442
    CrossrefPubMedSearch in Google Scholar
  • 41 Tolmachova T, Abrink M, Futter CE, Authi KS, Seabra MC. Rab27b regulates number and secretion of platelet dense granules. Proc Natl Acad Sci U S A 2007; 104 (14) 5872-5877
    CrossrefPubMedSearch in Google Scholar
  • 42 Hampson A, O'Connor A, Smolenski A. Synaptotagmin-like protein 4 and Rab8 interact and increase dense granule release in platelets. J Thromb Haemost 2013; 11 (01) 161-168
    PubMedSearch in Google Scholar
  • 43 Justa-Schuch D, Silva-Garcia M, Pilla E. , et al. DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. eLife 2016; 5: 5
    PubMedSearch in Google Scholar
  • 44 Durrant TN, van den Bosch MT, Hers I. Integrin αIIbβ3 outside-in signaling. Blood 2017; 130 (14) 1607-1619
    CrossrefPubMedSearch in Google Scholar
  • 45 Baig A, Bao X, Wolf M, Haslam RJ. The platelet protein kinase C substrate pleckstrin binds directly to SDPR protein. Platelets 2009; 20 (07) 446-457
    CrossrefPubMedSearch in Google Scholar
  • 46 Canobbio I, Visconte C, Momi S. , et al. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood 2017; 130 (04) 527-536
    CrossrefPubMedSearch in Google Scholar
  • 47 Humpel C. Platelets: their potential contribution to the generation of beta-amyloid plaques in Alzheimer's disease. Curr Neurovasc Res 2017; 14 (03) 290-298
    PubMedSearch in Google Scholar
  • 48 Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y. The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer's disease. Rev Neurosci 2017; 28 (08) 861-868
    PubMedSearch in Google Scholar
  • 49 Pinto-Fernandez A, Kessler BM. DUBbing cancer: deubiquitylating enzymes involved in epigenetics, DNA damage and the cell cycle as therapeutic targets. Front Genet 2016; 7: 133
    PubMedSearch in Google Scholar
  • 50 Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 2016; 7 (06) 6521-6537
    PubMedSearch in Google Scholar